DDInter1408 DDInter1619
Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2b. Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase
Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome . In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole .
Peginterferon alfa-2b {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ropinirole
Peginterferon alfa-2b {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methadone
Methadone {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Ropinirole
Peginterferon alfa-2b {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} (Compound) downregulates {v} (Gene) USP22
USP22 {u} (Gene) is downregulated by {v} (Compound) Ropinirole
Peginterferon alfa-2b {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rosuvastatin
Rosuvastatin {u} (Compound) downregulates {v} (Gene) GTF2A2
GTF2A2 {u} (Gene) is upregulated by {v} (Compound) Ropinirole
Peginterferon alfa-2b {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Dermatitis bullous {u} (Side Effect) is caused by {v} (Compound) Ropinirole
Peginterferon alfa-2b {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ethambutol
Ethambutol {u} (Compound) causes {v} (Side Effect) Visual impairment
Visual impairment {u} (Side Effect) is caused by {v} (Compound) Ropinirole
Peginterferon alfa-2b {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Ropinirole
Peginterferon alfa-2b {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is downregulated by {v} (Compound) Ropinirole
Peginterferon alfa-2b {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitavastatin
Pitavastatin {u} (Compound) upregulates {v} (Gene) MLLT11
MLLT11 {u} (Gene) is upregulated by {v} (Compound) Ropinirole
Peginterferon alfa-2b {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramelteon
Ramelteon {u} (Compound) palliates {v} (Disease) Parkinson's disease
Parkinson's disease {u} (Disease) is palliated by {v} (Compound) Ropinirole
Peginterferon alfa-2b may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ropinirole (Compound)
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Ropinirole (Compound)
Peginterferon alfa-2b may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Ropinirole (Compound)
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin (Compound) downregulates GTF2A2 (Gene) and GTF2A2 (Gene) is upregulated by Ropinirole (Compound)
Peginterferon alfa-2b may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) causes Dermatitis bullous (Side Effect) and Dermatitis bullous (Side Effect) is caused by Ropinirole (Compound)
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ethambutol and Ethambutol (Compound) causes Visual impairment (Side Effect) and Visual impairment (Side Effect) is caused by Ropinirole (Compound)
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Ropinirole (Compound)
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is downregulated by Ropinirole (Compound)
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) upregulates MLLT11 (Gene) and MLLT11 (Gene) is upregulated by Ropinirole (Compound)
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon and Ramelteon (Compound) palliates Parkinson's disease (Disease) and Parkinson's disease (Disease) is palliated by Ropinirole (Compound)